Olanzapine in the treatment of resistant depression.
Caetano
Dorgival
D
Caetano
Sheila C
SC
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D016642:Bupropion / Q000009:adverse effects / Q000627:therapeutic use; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077152:Olanzapine; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use*; D015430:Weight Gain / Q000187:drug effects
D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D016642:Bupropion; D001569:Benzodiazepines; D017374:Paroxetine; D000077152:Olanzapine